Ensysce Biosciences, Inc. (NASDAQ: ENSCW)

Ensysce Biosciences, Inc. (ENSC) is a clinical-stage pharmaceutical company that operates in the healthcare industry, specifically focused on developing innovative solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. The company's primary product candidate is PF614, a chemically modified, extended-release oxycodone-derivative designed to release clinically effective oxycodone only when exposed to specific physiological conditions in the gut.

Ensysce Biosciences' main business activities revolve around the development of product candidates designed to improve the safety and performance of prescription drugs, with a primary focus on opioid pain products and opioid use disorder products. The company's operations span across various countries and regions, including the United States, Australia, Brazil, Canada, China, Europe, Hong Kong, India, Japan, and Russia.

The company generates revenue through the development of its primary products and services, which include PF614 and PF614-MPAR. PF614 has been evaluated in a Phase 1 clinical study for safety and pharmacokinetics, and the results showed that it was well-tolerated and had a similar pharmacokinetic profile to OxyContin OP, a commercially available extended-release oxycodone product. PF614-MPAR, on the other hand, is a combination product that combines PF614 with nafamostat, a trypsin inhibitor. This combination product is designed to limit abuse potential by providing resistance to use through injection or inhalation and to provide overdose protection against excessive oral ingestion.

Ensysce Biosciences' position within the industry is strong, with a unique technology platform that utilizes a novel molecular delivery system designed to deter prescription drug abuse at the molecular level. The company's approach differs from current formulation-based strategies in several ways, including the use of a novel molecular delivery system, the ability to release clinically effective drugs only when exposed to specific physiological conditions, and the ability to limit bioavailability of active medication following co-ingestion of multiple doses. The company's key competitors include other pharmaceutical companies that are developing opioid pain products and opioid use disorder products.

The company's customers include healthcare providers and patients who are seeking innovative solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. The company's products are designed to be used in a variety of settings, including hospitals, clinics, and physician offices.

Ensysce Biosciences owns numerous patents and applications in the United States and significant commercial markets, including Australia, Brazil, Canada, China, Europe, Hong Kong, India, Japan, and Russia, relating to its product candidates. These patents and applications are projected to expire between 2028 and 2042, subject to any patent term adjustment or extension that might be available in a particular jurisdiction.

In terms of brand names, Ensysce Biosciences has developed PF614 and PF614-MPAR as its primary product candidates. The company's technology platform is known as TAAP. Additionally, Ensysce Biosciences has pending United States, PCT, and Taiwan applications directed to oral formulations of PF614-MPAR, and pending applications in the U.S., Canada, and Europe directed to the use of orally administered nafamostat for the treatment of infections caused by coronaviruses, including COVID-19.